Clear Harbor Asset Management LLC Buys Shares of 11,550 AnaptysBio, Inc. $ANAB

Clear Harbor Asset Management LLC bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the 2nd quarter, HoldingsChannel reports. The firm bought 11,550 shares of the biotechnology company’s stock, valued at approximately $780,000.

Other large investors have also recently made changes to their positions in the company. Persistent Asset Partners Ltd purchased a new position in shares of AnaptysBio in the second quarter valued at $39,000. Smartleaf Asset Management LLC lifted its holdings in AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares in the last quarter. Larson Financial Group LLC boosted its stake in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares during the period. Tower Research Capital LLC TRC boosted its stake in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ANAB shares. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Leerink Partners set a $90.00 target price on shares of AnaptysBio in a report on Friday, May 15th. Finally, UBS Group increased their target price on shares of AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $82.00.

AnaptysBio Stock Performance

Shares of ANAB opened at $57.74 on Monday. AnaptysBio, Inc. has a 12-month low of $11.40 and a 12-month high of $72.36. The company has a market cap of $1.71 billion, a PE ratio of -53.46 and a beta of 0.72. The stock has a 50-day moving average price of $58.56 and a 200-day moving average price of $58.83.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.